Popular GLP-1 receptor agonists - medications best known for revolutionizing diabetes care and weight management (think Ozempic, Wegovy, Mounjaro) - may offer an unexpected bonus: helping control asthma in people who are overweight or obese but do not have diabetes.
New research unveiled at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting analyzed real-world data from hundreds of patients with asthma. The results were striking: initiating treatment with a GLP-1 agonist was tied to significantly fewer severe asthma episodes (exacerbations) over time.
Overweight patients saw about a 14.6% lower risk of asthma flares.
Obese patients had a 12.2% reduction.
Those with morbid obesity experienced a 13.3% drop.
While GLP-1 drugs are already blockbuster treatments for metabolic conditions, this study (one of the largest of its kind in non-diabetic asthmatics) hints at broader benefits - possibly through reduced airway inflammation or other mechanisms.
The findings are promising but preliminary. They don't mean everyone with asthma should start these drugs - consult your allergist or pulmonologist. Still, it's an intriguing glimpse into how medications designed for one purpose might help in surprising ways for chronic respiratory conditions.